Format

Send to

Choose Destination
J Clin Neurosci. 2014 Mar;21(3):421-6. doi: 10.1016/j.jocn.2013.06.008. Epub 2013 Nov 11.

An audit of immunohistochemical marker patterns in meningioma.

Author information

1
Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, R3:02 KS, Stockholm S-17176, Sweden.
2
Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden.
3
Department of Neurosurgery, Alfred Hospital, Monash University, Melbourne, VIC, Australia.
4
Department of Clinical Neuroscience, Section of Neurosurgery, Karolinska Institute, R3:02 KS, Stockholm S-17176, Sweden. Electronic address: tiit.mathiesen@karolinska.se.

Abstract

Meningiomas may express a number of potentially growth-promoting receptors including receptors for progesterone, growth hormone and vascular endothelial growth factor (VEGF). These and other receptors are potential targets for chemotherapy. We have prospectively studied a panel of markers as a routine in order to obtain data of individual expression of markers that may provide targets for anti-receptor treatment. One hundred and seventy-five consecutive patients operated on for meningiomas between 2005 and 2008 were prospectively analysed with antibodies against receptors for growth hormone, insulin-like growth factor 1 (IGF-1), androgen receptors, progesterone receptors (PR) and antibodies against CD34, VEGF, Ki-67 and caspase-3. Expression of IGF-1 receptor (IGF-1r), epidermal growth factor receptor (EGFR) E30 and growth hormone receptor (GHr) was conserved across histological grades and found in 88% to 94% of meningiomas. PR were detected in 87%, but expression decreased in aggressive tumours. Angio-markers such as VEGF and CD34 were detected in 69% and 17% of meningiomas, respectively. Androgen receptors and caspase-3 were uncommon. The analyses of a panel were undertaken as a clinical routine in order to assess its feasibility and to provide data that can be utilised in a clinical setting. Three putative therapeutic receptor targets, IGF-1r, GHr and EGFR E30 were expressed in a large majority of tumours and in contrast to PR maintained expression despite increasing pathological grade of meningioma. Our data also suggest that anti-progesterone therapies and anti-angiogenic therapies could be targeted to subsets of meningioma patients who express PR or have CD34-positive tumours.

KEYWORDS:

EGF; IGF; Meningioma; Neurosurgery; Progesterone; VEGF

PMID:
24231566
DOI:
10.1016/j.jocn.2013.06.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center